Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.95
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.95
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$6.32 - $12.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)14.81K
Market Cap
$32.27M
Enterprise Value-$38.76
Total Cash (Recent Filing)$91.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.1
Beta0.75
Next Earnings
Nov 09, 2026EPS Estimate
-3.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)58.19
Shares Outstanding4,049,124
10 Day Avg. Volume16,344
30 Day Avg. Volume14,812
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.00Price Target Upside390.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-13.75
Revenue Forecast (FY)$6.76M
Bulls Say, Bears Say
Bulls Say
Differentiated Clinical PlatformThe non-PSMA CD46 approach and companion imaging agent give Kyntra a differentiated clinical and commercial position in mCRPC. The Phase II program is enrolling patients, with an interim readout expected in Q4 2026, creating a defined path to validate efficacy and patient selection.
Cash RunwayA projected cash runway into 2028 provides time to advance the FG-3246 Phase II program and prepare roxadustat for Phase III without an immediately necessary financing event. This supports continued development through multiple clinical milestones and reduces near-term liquidity pressure.
Reduced Future ObligationsThe amended royalty financing agreement materially lowers Kyntra’s maximum future payments and eliminates true-up obligations. Once the remaining $15M cap is satisfied, the company retains subsequent EVRENZO royalties in relevant territories, improving long-term cash flow retention and financial flexibility.
Bears Say
Revenue And Operating WeaknessThe sharp revenue contraction and deterioration in gross margin indicate that the current operating base is not producing dependable commercial earnings. Large operating losses increase reliance on cash reserves, licensing proceeds, or external financing while clinical programs require sustained investment.
Cash Burn And Negative EquityPersistent negative free cash flow means Kyntra continues consuming cash despite reported net income, while negative equity signals a weak capital cushion. Together, these conditions can constrain capital allocation and increase funding risk as the company expands late-stage clinical development.
Roxadustat Funding DependencyAdvancing and commercializing roxadustat may require external capital or a partnering transaction, creating uncertainty around execution and economics. Internal development would carry an AstraZeneca royalty, while partnering could transfer 35% of Kyntra’s economics and reduce future product value.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $6.32 and its highest was $12.58 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $32.27M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Nov 09, 2026 which is in 57 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Aug 13, 2026. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of -$3.184 by $6.144.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.66.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,049,124 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of $2.96 in its last earnings report, beating expectations of -$3.184. Following the earnings report the stock price went up 0.142%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyntra Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (390.57% Upside)
$39.00 (390.57% Upside)
Blogger Sentiment
Bearish
KYNB Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 58.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$39.00
▲(390.57% Upside)
Technical Analysis
Ownership Overview
3.37% Insiders
22.60% Mutual Funds
10.45% Other Institutional Investors
59.72% Public Companies and
Individual Investors